Thanks, though Graham seems to agree with my proposition:
"The VISION study compared Lu-PSMA-617 with standard of care in men with metastatic castrate-resistant prostate cancer (mCRPC) who had received at least two previous lines of therapy ...This compares with the LuPIN trial that tested the combination of Lu-PSMA-617 and Veyonda in men with end-stage mCRPC who had progressed on at least three previous lines of therapy."
(from today's announcement; my emphasis)
Novartis Vision trial result, page-11
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.009(9.38%) |
Mkt cap ! $30.68M | |||
| Open | High | Low | Value | Volume |
| 9.6¢ | 10.5¢ | 9.6¢ | $3.808K | 37.69K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10937 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 36068 | 2 |
View Market Depth
| Last trade - 15.59pm 02/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |